ArticleeNeuro2026
Therapeutic Potential of Platelet-Derived Growth Factor B-Modified Nanoparticles in Enhancing Pericyte Activation for Acute Ischemic Stroke.
Article in eNeuro, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-derived growth factor subunit B (PDGF-B) signaling plays a critical role in pericyte activation and neurovascular repair following ischemic injury. Although enhancing PDGF-B signaling in pericytes represents a promising therapeutic strategy for ischemic stroke, practical approaches have not yet been developed. In this study, we evaluated the therapeutic efficacy and underlying mechanisms of PDGF-B-modified heat shock protein nanoparticles (PDGF-B HSPNPs) in a transient middle cerebral artery occlusion mouse model of either sex. Mice were treated with single intravenous injection of PDGF-B HSPNPs immediately after reperfusion, and infarct volume and motor function were assessed. To investigate cellular effects, flow cytometric analysis of brain-derived single-cell suspensions was performed 3 d after treatment to quantify platelet-derived growth factor receptor β-positive pericytes. Our results demonstrate that PDGF-B HSPNPs administration significantly reduced infarct volume and improved motor function, accompanied by enhanced activation of pericytes in the peri-infarct region. These findings suggest that PDGF-B HSPNPs represent a promising therapeutic approach for the treatment of ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.